PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28176254-2	2018	18Fluorine-labeled sodium fluoride (18F-NaF) is a widely available radioisotope and PET imaging allows for absolute quantification of tracer uptake.	Fluorine-18	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	40-43	
33267660-7	2021	We compared the proportion of CCS progressors in 18F-NaF PET-positive versus 18F-NaF PET-negative coronary arteries.	Fluorine-18	49-52	C-X-C motif chemokine ligand 8	Homo sapiens	53-56	
33267660-11	2021	All subjects (100%, 15/15) with >=2 18F-NaF-positive coronary arteries progressed in CCS.	Fluorine-18	36-39	C-X-C motif chemokine ligand 8	Homo sapiens	40-43	
33380519-13	2021	Patients were injected a mean activity of 215.4+-31.3 MBq with estimated mean effective absorbed doses of 4.09+-0.59mSv for 18F-NaF PET and 7.88+-1.66 mSv for CT alone.	Fluorine-18	124-127	C-X-C motif chemokine ligand 8	Homo sapiens	128-131	
32915344-13	2020	The BPL can reduce PET acquisition to 90 s/bed in 18F-NaF PET/CT imaging.	Fluorine-18	50-53	C-X-C motif chemokine ligand 8	Homo sapiens	54-57	
30772226-10	2019	Lesions with 18F-NaF uptake had higher surrounding PCAT density than those without 18F-NaF uptake (-73 HU; interquartile range -79 to -68 vs. -86 HU; interquartile range -94 to -80 HU; p < 0.001).	Fluorine-18	13-16	C-X-C motif chemokine ligand 8	Homo sapiens	17-20	
30688757-1	2019	BACKGROUND: Fluorine-18-labeled sodium fluoride (F-NaF) uptake measured with PET in the vessel walls can indicate active microcalcification, a potential biomarker of higher-risk plaques, which are not indicated by macrocalcification measured with computed tomography (CT).	Fluorine-18	12-23	C-X-C motif chemokine ligand 8	Homo sapiens	51-54	
29293370-5	2018	We have analysed the relationship between 18F-NaF uptake in OA and associated symptoms of shoulder pain.	Fluorine-18	42-45	C-X-C motif chemokine ligand 8	Homo sapiens	46-49	
29555399-11	2018	A negative correlation was observed between 18F-NaF uptake and smooth muscle cell staining (IOD: r = -.710, P = .049).	Fluorine-18	44-47	C-X-C motif chemokine ligand 8	Homo sapiens	48-51	
30254551-8	2018	The sensitivity, specificity, and agreement rate of 18F-NaF PET/CT for detecting bone metastatic lesions were 98.3%, 65.7%, and 92.9%, respectively; these values were 42.9%, 97.1%, and 51.9%, respectively, for 18F-FDG PET/CT.	Fluorine-18	52-55	C-X-C motif chemokine ligand 8	Homo sapiens	56-59	
27879488-0	2017	18F-NaF PET Demonstrating Unusual Focal Tracer Activity in the Brain.	Fluorine-18	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	4-7	
28349280-6	2017	We then evaluated the relationship between 18F-NaF uptake (using the maximum target-to-background ratio, TBRmax, and the maximum blood-subtracted 18F-NaF activity, bsNaFmax, which was obtained by subtracting the SUVmax of each calcified plaque lesion and NaF-avid site from the SUVmean in the right atrium blood pool) and the change in calcified plaque volume and characteristics obtained after 1 year.	Fluorine-18	43-46	C-X-C motif chemokine ligand 8	Homo sapiens	47-50	
28860213-5	2017	These data suggest that dynamic [18F]-NaF PET may serve as a useful biomarker for facetogenic disability.	Fluorine-18	33-36	C-X-C motif chemokine ligand 8	Homo sapiens	38-41	
28764952-0	2017	Prospective comparison of 18F-NaF PET/CT versus 18F-FDG PET/CT imaging in mandibular extension of head and neck squamous cell carcinoma with dedicated analysis software and validation with surgical specimen.	Fluorine-18	26-29	C-X-C motif chemokine ligand 8	Homo sapiens	30-33	
27694173-6	2016	In summary, 18F-NaF PET/CT is a highly sensitive method, but 18F-fluorocholine PET/CT can detect early bone marrow metastases and provide greater specificity in the detection of bone metastases in patients with prostate cancer.	Fluorine-18	12-15	C-X-C motif chemokine ligand 8	Homo sapiens	16-19	
27573638-11	2017	Follow-up 18F-NaF PET/CT showed persistence of 81.5 % of the baseline 18F-NaF positive MM lesions after treatment, despite the fact that 64.7 % of them had turned to 18F-FDG negative.	Fluorine-18	10-13	C-X-C motif chemokine ligand 8	Homo sapiens	14-17	
27573638-11	2017	Follow-up 18F-NaF PET/CT showed persistence of 81.5 % of the baseline 18F-NaF positive MM lesions after treatment, despite the fact that 64.7 % of them had turned to 18F-FDG negative.	Fluorine-18	10-13	C-X-C motif chemokine ligand 8	Homo sapiens	74-77	
27445292-17	2016	18F-NaF PET demonstrates repeatability levels useful for clinically quantifying the response of bone lesions to therapy.	Fluorine-18	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	4-7	
25168931-1	2014	The functional imaging technique of dynamic fluorine-18 labeled sodium fluoride positron emission tomography ((18)F-NaF PET) allows the quantitative assessment of regional bone formation by measuring the plasma clearance of fluoride to bone at any site in the skeleton.	Fluorine-18	44-55	C-X-C motif chemokine ligand 8	Homo sapiens	116-119	
24318613-0	2014	Divergent determinants of 18F-NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score.	Fluorine-18	26-29	C-X-C motif chemokine ligand 8	Homo sapiens	30-33	
24701591-5	2014	Fluorine-18-NaF uptake in the heart and aorta increased significantly with advancing age.	Fluorine-18	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	12-15	
16236565-4	2005	We have done several experiments using the rat ulnar loading model that demonstrate that (1) high-resolution [18F]NaF PET can detect newly created microdamage in vivo; (2) the microdamage detected in this way is co-localized with damage detected by histological and autoradiographic procedures; and (3) high-resolution [18F]NaF PET can distinguish between the effects of mechanical loading that does not produce damage and fatigue loading that creates microdamage.	Fluorine-18	110-113	C-X-C motif chemokine ligand 8	Homo sapiens	114-117